Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,886,747
  • Shares Outstanding, K 161,332
  • Annual Sales, $ 1,039 M
  • Annual Income, $ -110,860 K
  • 60-Month Beta 0.97
  • Price/Sales 4.60
  • Price/Cash Flow 78.76
  • Price/Book 4.39
Trade ALKS with:

Options Overview Details

View History
  • Implied Volatility 39.22%
  • Historical Volatility 23.33%
  • IV Percentile 16%
  • IV Rank 14.32%
  • IV High 100.39% on 03/08/21
  • IV Low 29.00% on 08/02/21
  • Put/Call Vol Ratio 0.52
  • Today's Volume 167
  • Volume Avg (30-Day) 871
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 4,799
  • Open Int (30-Day) 7,314

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.07
  • Number of Estimates 3
  • High Estimate -0.03
  • Low Estimate -0.11
  • Prior Year 0.12
  • Growth Rate Est. (year over year) -158.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.26 +5.30%
on 09/07/21
31.52 -2.25%
on 08/31/21
+0.56 (+1.85%)
since 08/20/21
3-Month
23.11 +33.32%
on 07/15/21
31.52 -2.25%
on 08/31/21
+6.57 (+27.10%)
since 06/22/21
52-Week
15.35 +100.72%
on 10/28/20
31.52 -2.25%
on 08/31/21
+13.65 (+79.55%)
since 09/22/20

Most Recent Stories

More News
Alkermes to Take Part in the Cantor Virtual Global Healthcare Conference

/PRNewswire/ --  (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Cantor Virtual Global Healthcare Conference on at (). The presentation may be accessed under...

ALKS : 30.81 (+1.72%)
New Survey Provides Insights Into Drinking Behaviors During the Pandemic

/PRNewswire/ -- A new online survey conducted during the COVID-19 pandemic by The Harris Poll on behalf of Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), found that 17% of respondents aged...

ALKS : 30.81 (+1.72%)
Biogen's (BIIB) MS Drug, Vumerity, Gets Positive CHMP Opinion

The CHMP gives a positive opinion on, and recommends granting marketing authorization to Biogen's (BIIB) Vumerity for the treatment of adults with relapsing-remitting multiple sclerosis.

REGN : 647.06 (+0.02%)
BIIB : 289.32 (-2.10%)
RHHBY : 46.1100 (+0.30%)
ALKS : 30.81 (+1.72%)
Alkermes to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleukin Alfa, at the 2021 European Society for Medical Oncology (ESMO) Virtual Congress

/PRNewswire/ --  (Nasdaq: ALKS) today announced two poster presentations related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy,...

ALKS : 30.81 (+1.72%)
Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program

/PRNewswire/ --  (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards program on . This competitive grant program is designed to support...

ALKS : 30.81 (+1.72%)
Alkermes to Take Part in the Citi Annual BioPharma Virtual Conference

/PRNewswire/ --  (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Citi 16 Annual BioPharma Virtual Conference on at (). The presentation may be accessed under...

ALKS : 30.81 (+1.72%)
Alkermes' (ALKS) Drug Portfolio Aids Growth, High Reliance a Woe

Alkermes' (ALKS) portfolio of proprietary products drives growth while its pipeline progress has been impressive. However, heavy dependence on partners for royalty revenues remains a concern.

AZN : 58.74 (-0.66%)
JNJ : 163.93 (-0.36%)
MRK : 72.04 (+0.10%)
ALKS : 30.81 (+1.72%)
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance

The FDA accepts Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone, a potential treatment for schizophrenia.

REGN : 647.06 (+0.02%)
IRWD : 12.61 (-0.47%)
TEVA : 8.73 (+0.58%)
ALKS : 30.81 (+1.72%)
Why Is Alkermes (ALKS) Up 19.4% Since Last Earnings Report?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALKS : 30.81 (+1.72%)
Chart of the Day: Healthcare is Hot and so is Alkermes

The Barchart Chart of the Day belongs to the Biomedical company Alkermes (NASDAQ: ALKS ). I found the stock by using Barchart's powerful screening tools to find the stocks with the highest Weighted...

ALKS : 30.81 (+1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL CONSTA, the first and only long-acting atypical antipsychotic medication...

See More

Key Turning Points

3rd Resistance Point 31.97
2nd Resistance Point 31.43
1st Resistance Point 31.12
Last Price 30.81
1st Support Level 30.27
2nd Support Level 29.73
3rd Support Level 29.42

See More

52-Week High 31.52
Last Price 30.81
Fibonacci 61.8% 25.34
Fibonacci 50% 23.44
Fibonacci 38.2% 21.53
52-Week Low 15.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar